Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is well positioned to become a leader in the treatment of neuromuscular and cardiac diseases, with a strong pipeline and promising treatment candidates. With enough financial resources to support operations and upcoming trial milestones, the company has the potential to significantly improve the lives of patients with genetic diseases.

Bears say

Solid Biosciences is currently facing a number of challenges that could negatively impact the company's future growth prospects. These include the need for additional funding for the development of their gene therapy treatments, potential delays or increased requirements from regulatory agencies, and uncertainty surrounding the relationship between their surrogate marker and potential clinical benefits. While the company remains a top pick for a longer time horizon, the current FDA turmoil and general market conditions may lead to a shift in their target price, currently at $16. The recent resignation of FDA commissioner Marty Makary is not expected to impact the company's ongoing interactions with the agency, but data releases may be delayed as the company focuses on preserving data for discussions with FDA. Additionally, the company's recent dosing of SGT-212 in Friedreich's ataxia and expected data release by the end of 2026, as well as the upcoming dosing of SGT-501 in CPVT in 2H26, may provide some positive momentum, but it remains to be seen how these treatments will perform in clinical trials. The company's cash runway into 1H28 may provide some stability, but further funding will be needed for their pipeline programs. Overall, the company's current challenges and uncertainties make us believe that a negative outlook is warranted for their stock.

Solid Biosciences (SLDB) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Solid Biosciences (SLDB) has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.